Tempus cites real-world UK NHS study showing prostate pathology AI changes diagnosis in 5% of cases

• Tempus highlighted a Nature Digital Medicine study on real-world UK NHS deployment of the Paige Prostate AI Suite in prostate biopsy reporting.
• AI-assisted review led pathologists to change the initial diagnosis or Grade Group for 5% of patients; 1.3% could have altered clinical management.
• Labs reported faster turnaround times, with results potentially delivered nearly one day sooner than standard workflows.
• Study cited fewer requests for additional immunohistochemistry staining, indicating potential workflow relief for digital pathology labs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260716546846) on July 16, 2026, and is solely responsible for the information contained therein.